Cover Image
Market Research Report

Cardiac Marker Analyzer Product Analysis, Cardiac Marker Companies Business & Marketing Strategy

Published by iGate Research Pvt Ltd Product code 553477
Published Content info 100 Pages
Immediate Delivery Available
Price
Back to Top
Cardiac Marker Analyzer Product Analysis, Cardiac Marker Companies Business & Marketing Strategy
Published: August 9, 2017 Content info: 100 Pages
Description

Cardiac Marker analyzer represents a paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others.

The factors such as increasing incidences of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.

Key Highlights of the Report

  • Within the professional diagnostics business segment, Alere cardiometabolic net product sales and services revenue decreased by 12% in 2016.
  • In April 2017, Abbott and Alere Inc. announced that the companies have agreed to amend the existing terms of their agreement for Abbott's acquisition of Alere.
  • In 2016, Abbott Point of Care Diagnostics sales increased to over US$ 500 Million.
  • Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin.
  • A major focus of Response Biomedical development programs in cardiovascular testing has been clinical tests for the quantification of cardiovascular markers.
  • In February 2017, Siemens Healthineers announced a digital platform for healthcare providers as well as for providers of solutions and services.
  • Response Biomedical cardiovascular sales is likely to reach US$ XX Million by 2022.
  • Trinity Biotech Point-of-Care revenues for 2017 is likely to decline.
  • In Jan. 2017, Abbott completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena.

iGATE RESEARCH report titled “Cardiac Marker Analyzer Product Analysis, Cardiac Marker Companies Business & Marketing Strategy” provides a comprehensive assessment of the cardiac markers analyzer segments, comparative tests analysis, competitive product analysis, product features & benefits, merger, acquisitions, strategic alliances and Companies Business and Market Strategies.

This 100 Page report with 7 Figures and 18 Tables has been studied from 6 View Points:

  • 1. Cardiac Marker Companies - Comparative Tests Analysis
  • 2. Cardiac Marker Analyzer - Competitive Product Analysis
  • 3. Cardiac Marker Analyzer - Specifications, Product Features & Benefits Analysis
  • 4. Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
  • 5. Emerging Markers Analysis
  • 6. Companies Business & Marketing Strategy

12 Cardiac Marker Analyzer Covered in the report are as follows:

  • 1. Triage MeterPro Analyzer
  • 2. The i-STAT System
  • 3. Cobas h 232 POC System
  • 4. Access 2 Immunoassay System
  • 5. Stratus CS Analyzer
  • 6. RAMP 200
  • 7. RAMP Reader
  • 8. i-chroma DUO Analyzer
  • 9. DXpress Reader Analyzer
  • 10. PATHFAST Analyzer
  • 11. QL Care Analyzer
  • 12. Meritas POC Analyzer

Cardiac Marker Analyzer - Key Companies Analysis

  • 1. Alere
  • 2. Abbott Point of Care
  • 3. Roche
  • 4. Beckman Coulter
  • 5. Siemens Healthineers
  • 6. Response Biomedical
  • 7. Boditech
  • 8. Lifesign
  • 9. LSI Medience Corporation
  • 10. CardioGenics Holdings Inc.
  • 11. Trinity Biotech

Data Sources:

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies:

  • Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
  • Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
Table of Contents

Table of Contents

1. Executive Summary

2. Cardiac Marker Companies-Comparative Tests Analysis

3. Cardiac Marker Analyzer-Competitive Product Analysis

4. Alere

  • 4.1. Alere Triage
    • 4.1.1. Triage MeterPro Analyzer
    • 4.1.2. Alere Cardiology Net Sales & Forecast (2010-2016)

5. Abbott Point of Care

  • 5.1. The i-STAT System
  • 5.2. Abbott Laboratories Point of Care Diagnostics Sales (2011-2022)

6. Roche

  • 6.1. Cobas h 232 POC System

7. Beckman Coulter

  • 7.1. Access 2 Immunoassay System

8. Siemens Healthineers

  • 8.1. Stratus CS Analyzer
  • 8.2. Siemens Healthineers establishes global Digital Ecosystem to drive Digitalization of Healthcare

9. Response Biomedical

  • 9.1. Cardiovascular Testing
    • 9.1.1. Acute Myocardial Infarction (Heart Attack) Testing
    • 9.1.2. Congestive Heart Failure (“CHF”) Testing
    • 9.1.3. Thrombotic Disease Testing
  • 9.2. RAMP Platform
    • 9.2.1. RAMP 200
    • 9.2.2. RAMP Reader
  • 9.3. Response Cardiovascular Testing
    • 9.3.1. RAMP® TROPONIN I
    • 9.3.2. RAMP® NT-proBNP
    • 9.3.3. RAMP® MYOGLOBIN
    • 9.3.4. RAMP® CK-MB
    • 9.3.5. RAMP® D-DIMER
    • 9.3.6. Response Biomedical Cardiovascular Net Sales (2010-2022)

10. Boditech

  • 10.1. i-chroma DUO Analyzer

11. Lifesign

  • 11.1. DXpress Reader Analyzer

12. LSI Medience Corporation

  • 12.1. PATHFAST Analyzer

13. CardioGenics Holdings Inc.

  • 13.1. QL Care Analyzer

14. Trinity Biotech

  • 14.1. Meritas POC Analyzer
  • 14.2. Trinity Biotech Point of Care Diagnostics Sales (2010-2022)

15. Mergers, Acquisitions and Licensing Agreements

  • 15.1. Alere Inc
  • 15.2. CardioGenics
  • 15.3. Response Biomedical
  • 15.4. Abbott Laboratories
  • 15.5. Siemens Healthineers
  • 15.6. LSI Medience Corporation
  • 15.7. Trinity Biotech

16. Emerging Markers

17. Response Biomedical-Business & Marketing Strategy

  • 17.1. New Distributors in China
  • 17.2. Strategic Alliances with Alere Medical in Japan
  • 17.3. Response Biomedical Receives Health Canada Approval and CE Mark

18. Roche-Business & Marketing Strategy

  • 18.1. Implementing the Fully Connected Core Laboratory
  • 18.2. Broadening the Diagnostics Portfolio
  • 18.3. Roche Launches Point-Of-Care (POC) Troponin Test with Improved Accuracy
  • 18.4. Roche Launches New Mobile Application for Tablets

19. Boditech Med Inc-Business and Marketing Strategy

  • 19.1. Boditech Med Acquires Immunostics
  • 19.2. Marketing Channel

20. Siemens Healthineers-Business and Marketing Strategy

  • 20.1. Siemens Healthineers Announces New Strategic Relationship
  • 20.2. Cloud-Based Network Teamplay from Siemens Healthineers
  • 20.3. Strategic Partnership between Siemens and Imricor
  • 20.4. Siemens Healthineers Offers True High-Sensitivity Troponin I IVD Assay
  • 20.5. Siemens Healthineers Establishes Global Digital Ecosystem to Drive Digitalization of Healthcare
  • 20.6. Partnership between Siemens Healthineers and Ebit

List of Figures:

  • Figure 4-1: Global-Alere Cardiology Net Sales (Million US$), 2010-2016
  • Figure 5-1: Global-Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2011-2016
  • Figure 5-2: Global-Forecast for Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2017-2022
  • Figure 9-1: Global-Response Biomedical Cardiovascular Product Sales (Million US$), 2010-2016
  • Figure 9-2: Global-Forecast for Response Biomedical Cardiovascular Product Sales (Million US$), 2017-2022
  • Figure 14-1: Global-Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2010-2016
  • Figure 14-2: Global-Forecast for Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2017-2022

List of Tables:

  • Table 2-1: Cardiac Marker Companies-Comparative Tests Analysis
  • Table 2-2: Cardiac Marker Companies-Comparative Tests Analysis
  • Table 2-3: Cardiac Marker Companies-Comparative Tests Analysis
  • Table 3-1: Cardiac Marker Analyzer-Competitive Product Analysis
  • Table 3-2: Cardiac Marker Analyzer-Competitive Product Analysis
  • Table 4-1: Alere Triage Product Analytes
  • Table 12-1: PATHFAST-Technical Specifications
  • Table 15-1: Alere-Merger & Acquisition, 2007-2017
  • Table 15-2: Alere-Distribution/Partnership Agreement, 2008, 2016
  • Table 15-3: CardioGenics-Mergers & Acquisition, 2015
  • Table 15-4: CardioGenics-Licensing Agreement, 2012
  • Table 15-5: Response Biomedical-Distribution Agreement, 2011-2015
  • Table 15-6: Response Biomedical-Collaboration Deal, 2004-2015
  • Table 15-7: Abbott Laboratories-Merger & Acquisition, 2003, 2017
  • Table 15-8: Siemens Healthineers-Merger & Acquisition, 2017
  • Table 15-9: Siemens Healthineers-Strategic Partnership, 2017
  • Table 15-10: LSI Medience Corporation-Strategic Alliance, 2014
  • Table 15-11: Trinity Biotech-Merger & Acquisition, 2012
Back to Top